This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

EV1014

Psychedelic drugs in psychiatry: on psilocybin

PSYCHEDELIC DRUGS IN PSYCHIATRY: LET’S TALK ABOUT PSILOCYBIN

The current literature suggests that, under controlled and monitored conditions, psilocybin may offer potential benefits in areas such as treatment-resistant depression, alcohol use disorder, and pain management in palliative care.

The aim is to examine the therapeutic effects of psychedelics, particularly psilocybin, in the treatment of various psychiatric disorders through the current literature. The method is a literature review of publications selected for their relevance to the study objectives. Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indole-based secondary metabolite produced by numerous mushroom species and has recently been studied for its potential benefits in addictions, particularly alcohol use disorder, and in pain relief in palliative care. In 2021, a randomized controlled phase 2b trial investigating psilocybin-assisted therapy for treatment-resistant depression, in which the Champalimaud Foundation in Lisbon participated, enrolled 233 participants; a single 25 mg dose of psilocybin administered with psychological support produced a significant reduction in depressive symptoms. Changes in neuronal reactivity and emotional components induced by psilocybin therapy in alcohol use disorder were examined; increased activity was observed in the medial and lateral prefrontal cortex and the left caudate nucleus, while decreased activity was found in the insular, motor, temporal, parietal, and occipital cortices and the cerebellum. These changes were associated with improved emotion regulation and reduced craving. In palliative care, case reports suggest that psilocybin may be a safe and effective option for pain relief through mechanisms consistent with current knowledge of nociception and central sensitization; recent studies in major depressive disorder also report clinically significant improvements in depressive symptoms. Psilocybin was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression in 2018 and for major depression in late 2019.

All WCP 2026 summaries